IDO1 and glioblastoma: In addition, the antitumor efficiency of IDO1 inhibitors (e.g., BMS-986205 and indoximod) combined with RT and TMZ is also currently under investigation in different clinical trials (NCT04047706 and NCT02052648) for newly diagnosed GBM patients.